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ABSTRACT
Understanding the role of autophagy in cancer has been limited by the inability to measure this dynamic
process in formalin-fixed tissue. We considered that 3-dimensional models including ex vivo tumor, such as
we have developed for studying mesothelioma, would provide valuable insights. Using these models, in
which we could use lysosomal inhibitors to measure the autophagic flux, we sought a marker of autophagy
that would be valid in formalin-fixed tumor and be used to assess the role of autophagy in patient outcome.
Autophagy was studied in mesothelioma cell lines, as 2-dimensional (2D) monolayers and 3-dimensional (3D)
multicellular spheroids (MCS), and in tumor from 25 chemonaive patients, both as ex vivo 3D tumor
fragment spheroids (TFS) and as formalin-fixed tissue. Autophagy was evaluated as autophagic flux by
detection of the accumulation of LC3 after lysosomal inhibition and as autophagy initiation by detection of
ATG13 puncta. We found that autophagic flux in 3D, but not in 2D, correlated with ATG13 positivity. In each
TFS, ATG13 positivity was similar to that of the original tumor. When tested in tissue microarrays of 109
chemonaive patients, higher ATG13 positivity correlated with better prognosis and provided information
independent of known prognostic factors. Our results show that ATG13 is a static marker of the autophagic
flux in 3D models of mesothelioma and may also reflect autophagy levels in formalin-fixed tumor. If
confirmed, this marker would represent a novel prognostic factor for mesothelioma, supporting the notion
that autophagy plays an important role in this cancer.
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Introduction
Macroautophagy (hereafter referred to as autophagy), a degra-
dation process that eliminates dysfunctional proteins and
organelles and thereby provides energy and amino acids, may
play an important role in cancer, although its actual role is still
unclear. Autophagy can play a dual role and both inhibition
and stimulation of autophagy have been discussed as potential
approaches in cancer therapy.1-7 Some of the confusion about
the role of autophagy in cancer may arise from the difficulties
in measuring the dynamic process of autophagy in formalin-
fixed tumor specimens.2,8,9 The analysis of autophagy in tumor
samples will be necessary to understand the level of autophagy
at basal conditions and after modulation and perhaps to
determine which strategy, either autophagy inhibition or
stimulation, would be a more effective therapeutic approach.
Currently, autophagy is most accurately measured by determin-
ing the autophagic degradation activity, referred to as autopha-
gic flux, which requires inhibition of lysosomal proteases,
something that clearly cannot be performed in fixed clinical
samples.2,8-12 The study of autophagy in cancer would be
advanced by finding static markers in fixed tumor that correlate
with the dynamic process of autophagy.
Thus, there is a need for models that provide useful informa-
tion about autophagy in tumor. In this regard, 3D cultures of
cancer cell lines are increasingly used as clinically relevant
models for the study of autophagy.13-15 Nevertheless, the find-
ings in in vitro 3D models are limited without a correlation to
the autophagic flux in actual tumor. We considered that an ex
vivo 3D tumor model in which lysosomal inhibitors could be
used ex vivo would enable measurement of autophagic flux in
actual tumor. Knowing the autophagic flux in ex vivo tumor,
we could then seek accurate markers that could be applied to
fixed tumor samples.
In our work in malignant pleural mesothelioma, a highly
chemoresistant solid tumor, we have established an ex vivo
3D model of living tumor, the tumor fragment spheroid
(TFS) model,16 which has been useful for studying tumor
biology.17-19 Here, we measured the levels of autophagy in
2D monolayers and in our 3D models, including ex vivo
TFS. We then asked whether the levels of autophagic flux,
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as measured in 3D models, correlated with a static marker
of autophagy that could be measured in fixed tumor sam-
ples and, if so, whether such a marker would correlate with
clinical outcome.
Results
In 3D multicellular spheroids, autophagic flux differs from
that measured in 2D
To determine whether autophagy differs in 2D and 3D, we
measured the autophagic flux in cell lines grown in both set-
tings. The autophagic flux was determined by inhibiting the
degradation function of lysosomes and then measuring the
accumulation of lipidated microtubule-associated protein 1
light chain 3 isoform B (LC3B-II), by immunoblotting, or of
autophagic vesicles loaded with LC3B-II, by immunofluores-
cence.9,10 Six malignant pleural mesothelioma cell lines grown
as monolayers (2D) or as multicellular spheroids (MCS, 3D)
were exposed or not exposed to the lysosomal inhibitor ammo-
nium chloride (NH4
C) for 8 h.
By LC3 immunoblotting (Fig. 1), we found that, for each cell
line, the autophagic flux differs between 2D and 3D cultures.
The autophagic flux was lower in 3D than in 2D in 3 cell lines
(Fig. 1, MCS-low autophagy), and higher in 3D than in 2D in
the other 3 (Fig. 1, MCS-high autophagy). The autophagic flux
in 3D did not correlate with that in 2D.
By LC3 immunofluorescence, we verified the levels of auto-
phagic flux in each cell line (Fig. 2A). Autophagic vesicles
loaded with LC3B-II were counted as LC3 puncta and the ratio
between LC3 puncta detected in NH4
C-exposed and control
unexposed cells is shown in Figure 2B. These findings confirm
that autophagy in 3D differs from that in 2D.
We considered that some lysosomal inhibitors, including
NH4
C, may activate autophagy, especially at longer exposures.9
Thus, we repeated the experiment with a second inhibitor and
for a shorter duration of exposure. The 6 cell lines grown as 2D
or 3D were exposed or not exposed to NH4
C or to hydroxy-
chloroquine (HCQ), as an additional lysosomal inhibitor, for
4 h (Fig. S1). In this experiment, we confirmed the previous
results, showing that there are 2 groups of mesothelioma cell
lines that exhibit low or high autophagic flux in 3D and that
the autophagic flux in 3D does not correlate with that in 2D.
The 2 inhibitors, NH4
C and HCQ, led to the same conclusion
for each cell line.
In 3D multicellular spheroids, but not in 2D, autophagic
flux appears to correlate with the autophagy initiation
status (ATG13 puncta)
We next focused on uncovering a marker of autophagy whose
static measurement would reflect the autophagic flux in meso-
thelioma cell lines, allowing assessment of autophagy without
the need for lysosomal inhibition. We considered that auto-
phagy proteins involved in the early phases of autophagy would
possibly reflect the autophagic flux. In particular, we focused on
proteins of the 2 complexes that signal the onset of autophagy:
the BECN1/Beclin 1-class III phosphatidylinositol 3-kinase and
ULK1 complexes.
Figure 1. In mesothelioma cells, LC3 immunoblotting shows that autophagic flux differs between 2D and 3D cultures. (A) Cells were grown as monolayers (2D) or MCS
(3D). Where indicated, the cells were exposed to 10 mM ammonium chloride (NH4
C) for 8 h. LC3B expression was assessed by immunoblotting. As a loading control, filters
were probed with anti TUBA/a-tubulin antibody. Band intensities were determined by densitometric analysis. The autophagic flux is expressed as a ratio of normalized
LC3B-II band intensities after NH4
C to before NH4C (NH4C:CTRL). A representative immunoblot of 3 independent experiments is shown, with ratios shown below. (B) Bars
show the autophagic flux of 2D (light gray) or 3D (dark gray) cultures of the indicated cell lines. Data were obtained from 3 independent experiments, one of which is
shown in (A). Asterisks indicate statistically significant differences of autophagic flux between 2D and 3D (P< 0.05). Error bars, SD. The mean LC3-II ratios in 3D are signifi-
cantly higher in MCS-high autophagy than in MCS-low autophagy cell lines (P < 0.05).
AUTOPHAGY 1181
The first regulatory complex includes BECN1, which is an
autophagy-related protein.9 Moreover, BECN1 expression level
correlates with patient outcome in other tumors.20-30 However,
we found that BECN1 expression in the 6 mesothelioma cell
lines grown as 2D or 3D does not reflect their level of autopha-
gic flux (Fig. S2A).
The second regulatory complex, the ULK1 complex, includes
ATG13, which is of pivotal importance to autophagy initiation.31-33
The activity of the ULK1 complex can be assessed by the formation
of puncta by its subunits, including ATG13, representing relocation
of the complex to the autophagosome, as the earliest event in
autophagy initiation.34 Indeed, we recently have found that ATG13
puncta are present in MCS with high autophagy.35 Therefore, we
asked whether ATG13 puncta reflect the autophagic flux of the cell
lines in either the 2D or 3D setting.
In 2D monolayer cultures of all cell lines, ATG13 puncta
were almost undetectable (Fig. 3; 2D) whether or not the cell
lines had a high autophagic flux in 2D (see Fig. 1). We con-
cluded that the autophagy initiation status did not reflect the
autophagic flux in 2D.
However, in 3D, ATG13 puncta did reflect the autophagic
flux. In MCS with low autophagy, ATG13 puncta staining was
weak and was seen only in a few cells (Fig. 3; 3D, MCS-low
autophagy) whereas, in MCS with high autophagy, ATG13
puncta staining was strong and seen in many cells (Fig. 3; 3D,
MCS-high autophagy).
Interestingly, the level of ATG13 protein did not
reflect the differences seen in ATG13 puncta (Fig. S2A
and S2B). Although a difference was found between the
low and high autophagy cell lines, the level of ATG13
protein did not differ between 2D and 3D and thus did
not reflect the presence of ATG13 puncta nor the auto-
phagic flux. We concluded that ATG13 protein levels
remain fairly constant independent of the aggregation of
the proteins in puncta and the level of autophagic flux.
Our data suggest that in 3D, but not in 2D, cultures
the presence of ATG13 puncta (but not ATG13 protein
levels) could identify mesothelioma cells with either low
or high autophagic flux at basal conditions, without the
need for lysosomal inhibitors.
Figure 2. In mesothelioma cells, LC3 immunofluorescence confirms that autophagic flux differs between 2D and 3D cultures. (A) Cells were grown as in Fig. 1, trypsinized
and cytospun on glass slides. Cells were then fixed and stained for LC3B (green) and nuclei (blue) and imaged by confocal microscopy. Arrowheads indicate LC3 puncta.
Representative cells of 2 independent experiments are shown. Scale bars: 10 mm. (B) Bars show the ratio between LC3 puncta counted in cells grown in the presence or
absence of 10 mM ammonium chloride (NH4
C). Asterisks indicate significantly different LC3 puncta ratios between 2D and 3D (P< 0.05). Error bars, SD. The mean LC3
puncta ratios in 3D are also significantly higher in MCS-high autophagy than in MCS-low autophagy cell lines (P < 0.05).
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Because ATG13 puncta did not reflect the high autophagic
flux in 2D cultures of the MCS-low autophagy group (Fig. 3;
top left, 2D, MCS-low autophagy), we considered that ATG13
puncta formation might be defective in that 2D setting. We
therefore repeated the analysis of ATG13 puncta in the 6 meso-
thelioma cell lines after stimulating autophagy with Earle’s bal-
anced salt solution (EBSS). Under these nutrient deprivation
conditions, ATG13 puncta were detectable in all the cell lines
grown in both 2D and 3D (Fig. S3). In addition, LC3 puncta
analysis, performed in 2 cell lines representative of the MCS-
low or MCS-high autophagy groups, confirmed that EBSS
induced a high autophagic flux both in 2D and 3D (Fig. S4),
matching the observation with ATG13 puncta. Thus, the
absence of ATG13 puncta in 2D at basal conditions did not
represent an inability to form ATG13 puncta but may indicate
that, in 2D basal conditions, autophagy initiation does not
involve ATG13.
We conclude that, in 3D, the presence of ATG13 puncta is use-
ful to identify mesothelioma cells with either low or high autopha-
gic flux, during both basal and stimulated autophagy. In 2D, on the
other hand, ATG13 puncta reflect the presence of cells with high
autophagic flux only after a strong stimulation of autophagy.
In ex vivo tumor fragment spheroids, autophagic flux was
assessed by the percentage of cells containing LC3 puncta
and reveals tumors with either low or high autophagy
Building on our measurements of autophagic flux in cell lines,
we now aimed to measure autophagic flux in ex vivo tumor
itself, using tumor fragment spheroids (TFS) generated from
tumor resected from 25 chemonaive MPM patients. In TFS,
where it was not possible to determine mesothelioma-cell spe-
cific LC3 accumulation by immunoblotting, we relied on
immunofluorescence, in which mesothelioma cells were identi-
fied by KRT/cytokeratin staining. Because the LC3 puncta over-
lapped each other in the tissue sections and could not be
individually counted, we counted the percentage of KRT/cyto-
keratin-positive cells containing LC3 puncta (LC3B-II-positive
MPM cells x100/total MPM cells). TFS were grown in the
presence or absence of NH4
C and the percentage of LC3-posi-
tive MPM cells was measured.
In TFS not exposed to NH4
C, few cells with LC3 puncta
were detected (Fig. 4A and B; CTRL). In TFS exposed to NH4
C,
the percentage of LC3-positive MPM cells in the TFS increased
to different degrees identifying 2 groups: approximately half
the TFS had a small increase, defining a TFS-low autophagy
group, and the other half had a large increase, defining a TFS-
high autophagy group (Fig. 4A and B; NH4
C). On average, the
percentage of LC3-positive cells increased by less than 2-fold
(from 1.7% to 2.9% of MPM cells) in the TFS-low autophagy
and by 8-fold (from 2.5% to 20.8% of MPM cells) in the TFS-
high autophagy (Table 1).
We note that, in each TFS, even in the high autophagy group,
there were mesothelioma cells that did not show LC3 puncta
after exposure to NH4
C. We concluded that 2 populations of
mesothelioma cells, with either undetectable or detectable auto-
phagic flux, existed in different percentages in each TFS.
Our data show that ex vivo mesothelioma can have either a
low or high level of autophagy, as determined by the percentage
of tumor cells that demonstrate autophagy within the TFS. These
measurements represent the first time that autophagy has been
measured in living mesothelioma tumor grown ex vivo.
In ex vivo tumor fragment spheroids, autophagic flux
correlates with the autophagy initiation status (ATG13
puncta)
To determine whether ATG13 would be a useful marker of
autophagic flux in ex vivo tumor, as in 3D MCS, we measured
the percentage of MPM cells containing ATG13 puncta in TFS
not exposed to NH4
C. In the TFS previously identified as hav-
ing low autophagy (Fig. 4), we observed a low percentage of
mesothelioma cells with ATG13 puncta (ATG13-positive
MPM cells) (Fig. 5A and B; TFS-low autophagy) and, in the
TFS previously identified as having high autophagy, we found a
high percentage of ATG13-positive cells (Fig. 5A and B; TFS-
high autophagy).
Figure 3. In mesothelioma cells, ATG13 puncta reflect the autophagic flux only in 3D. Mesothelioma cells were grown as monolayers (2D) on coverslips or as MCS (3D).
Spheroid cells were trypsinized and cytospun on glass slides. Cells adherent on cover slips or glass slides were then fixed, stained for ATG13 (green) and nuclei (blue),
and imaged by confocal microscopy. Representative ATG13 puncta are indicated by arrowheads. Scale bars: 10 mm.
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Notably, the percentages of ATG13-positive MPM cells (at
baseline) correlated with those of LC3-positive MPM cells (after
lysosomal inhibition) (Fig. 6A). We considered whether the same
cells were positive for both ATG13 and LC3. Double staining for
ATG13 and LC3A/B was then performed in a TFS with high
autophagy, grown in the presence or absence of NH4
C. As shown
in Figure 6B, we observed that, without NH4
C, ATG13 staining
was seen but no LC3. After NH4
C, the LC3 staining increased and,
except for a few cells that stained for only onemarker, LC3 staining
was seen in the cells that also showed ATG13 puncta. The
colocalization indicated that, at a cellular level, autophagy initiation
corresponded with autophagic flux.
In ex vivo tumor fragment spheroids, autophagy initiation
(ATG13 puncta) correlates with that in the original
formalin-fixed tumors
To test whether the levels of autophagy initiation measured in
the TFS matched those of the original tumors from which they
Figure 4. In tumor fragment spheroids, LC3 immunofluorescence indicates low or high levels of autophagy. TFS were generated from tumor biopsies obtained from 25
chemonaive MPM patients and grown in the presence or absence of ammonium chloride (NH4
C) for 12 h. TFS were then fixed, embedded in paraffin, stained for LC3B
(green), KRT/cytokeratin to identify mesothelioma cells (red), and nuclei (blue), and imaged by confocal microscopy. (A) Bars represent the mean percentage of LC3-posi-
tive MPM cells measured in TFS grown in the presence (gray bars) or absence (white bars) of NH4
C. Error bars, SEM (B) Representative images of TFS with either low (TFS
#8) or high (TFS #2) autophagy levels are shown, with the percentage of mesothelioma cells with LC3 puncta (LC3-positive MPM cells) indicated in parentheses. Zoom-in
view of the region in the dashed box shows representative cells with LC3 puncta (arrowhead). Scale bars: 10 mm.
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were generated, we performed ATG13 immunostaining in sec-
tions of the tumors used to generate the TFS we studied. Our
results show that the percentage of MPM cells with ATG13
puncta in the TFS reflected that of the original tumors
(Fig. 7A and B).
Thus, for each individual tumor, the autophagy initiation
status of the ex vivo TFS, even after at least 2 wk in culture,
closely resembles the autophagy initiation status of the original
tumor, supporting the notion that the ex vivo TFS model is use-
ful for studying autophagy in mesothelioma.
In patients with mesothelioma, ATG13, the marker
of autophagy initiation, correlates with clinical outcome
To learn whether ATG13 puncta positivity could reveal
useful information about tumors in patients with mesothe-
lioma, we measured the percentage of cells with ATG13
puncta in tissue microarrays comprising clinical samples
from a total of 109 MPM patients who had undergone
surgical resection without prior chemotherapy. Overall,
the median percentage of ATG13-positive MPM cells
detected in our patient cohort was 8% (range 0% to 32%;
inter-quartile range 2% to 19%). To assess the relationship
of ATG13 positivity to patient outcome, we first compared
Kaplan-Meier estimates of overall survival and time to
recurrence following surgery among 4 groups comprising
the ATG13 quartiles. An increasing proportion of tumor
cells with punctate ATG13 staining was associated with
incrementally improved survival functions. Next, we used
Cox regression to determine the optimal cutpoint for a
categorical parameter representing “high” and “low” levels
of ATG13 positivity. We compared relative risk deter-
mined for death and recurrence at each of 18 candidate
cutpoints defined by segmenting the inter-quartile range
in 1% increments. Whereas the univariate hazard ratios
associated with all candidate cutpoints within the inter-
quartile range were similar for both overall survival (0.51
to 0.64) and time to recurrence (0.39 to 0.58), we selected
the 6% cutpoint because it optimally minimized hazard
ratios for both endpoints (univariate and with correction
for tumor histology), and divided the cohort fairly evenly,
with 58% of patients categorized high and 42% low
ATG13 positivity (Fig. 8A).
At the 6% cutpoint, median overall survival was significantly
longer for patients with high ATG13 positivity (6% ATG13-
positive tumor cells; 17.4 mo) than for those with low positivity
(<6 % ATG13-positive tumor cells; 10.6 mo) (P D 0.0009;
Bonferroni corrected PD0.0162). Time to recurrence was also
significantly longer for patients with high ATG13 positivity
(13.7 mo) than for low positivity (6.6 mo) (P < 0.0001;
Bonferroni corrected P < 0.0018) (Fig. 8B).
ATG13 positivity was more commonly low among non-
epithelioid tumors (P D 0.01), but was not correlated with
other known prognostic factors including age, lymph node
status, gender, tumor volume, anemia, resectability, surgical
procedure, adjuvant therapy, or TNM stage (Fig. 8C). To
address the possibility that histology was driving the out-
come differences observed with ATG13, we performed a
multivariate analysis adjusting for histology. In this analysis,
after adjusting for histology, ATG13 positivity remained sig-
nificantly prognostic for overall survival and time to recur-
rence (Fig. 8D). When applying a conservative correction
for the multiple comparisons required to establish the cut-
point, ATG13 positivity level remained significantly prog-
nostic for time to recurrence but not for overall survival
(Fig. 8D).
We conclude that the autophagy initiation, as assessed by
the percentage of cells with ATG13 puncta, correlated with
clinical outcome of patients with mesothelioma and pro-
vided prognostic information independent of its association
with epithelioid histology, indicating that higher autophagy
initiation is associated with better outcome. However, we
acknowledge that validation of the selected cutpoint and
effect sizes will be required in additional patient cohorts,
given the known pitfalls of dichotomizing continuous
covariates.36
Table 1. In tumor fragment spheroids, LC3-positivity is shown at baseline and after ammonium chloride (NH4
C) treatment. The percentages of LC3-positive MPM cells are
shown for low (A) or high (B) autophagy TFS grown in the presence (NH4
C) or absence (CTRL) of ammonium chloride. For each TFS, data are expressed as mean percen-
tages. Parentheses, SEM. The difference in the percentage of LC3B-positive MPM cells following exposure to ammonium chloride (NH4
C-CTRL) is also shown for each TFS.
(A) TFS-low autophagy (B) TFS-high autophagy
TFS #
LC3 CTRL %
of LC3-positive
MPM cells (SEM)
LC3 NH4
C % of
LC3-positive
MPM cells (SEM)
LC3 difference
(NH4
C - CTRL) TFS #
LC3 CTRL % of
LC3-positive MPM
cells (SEM)
LC3 NH4
C
% of LC3-positive
MPM cells (SEM)
LC3 difference
(NH4
C - CTRL)
1 1.4 (0.8) 1.6 (0.5) 0.2 2 2.3 (0.2) 26.3 (2.1) 24.0
3 1.1 (1.1) 1.6 (0.9) 0.5 4 2.9 (0.7) 37.4 (3.0) 34.5
7 0.4 (0.4) 1.0 (1.0) 0.6 5 1.9 (0.2) 16.6 (3.2) 14.7
8 1.4 (0.1) 2.3 (0.4) 0.9 6 1.7 (0.3) 18.1 (2.5) 16.5
9 0.4 (0.4) 0.9 (0.5) 0.5 11 2.3 (0.6) 16.8 (0.9) 14.5
10 0.5 (0.5) 1.0 (1.0) 0.5 12 2.2 (0.6) 11.6 (3.0) 9.4
13 1.0 (1.0) 0.7 (0.7) ¡0.2 14 2.0 (0.9) 21.6 (1.2) 19.6
15 3.0 (0.7) 6.0 (0.1) 3.0 16 1.9 (0.0) 17.5 (1.2) 15.6
17 1.9 (1.0) 3.9 (0.7) 2.0 18 4.8 (2.4) 29.6 (1.9) 24.9
20 3.3 (0.5) 6.6 (1.3) 3.3 19 2.2 (0.7) 15.1 (2.3) 12.8
21 3.1 (1.7) 4.9 (1.2) 1.8 23 2.8 (0.4) 18.0 (4.1) 15.2
22 3.0 (0.3) 5.4 (0.7) 2.4 25 3.3 (1.1) 21.2 (2.7) 17.9
24 1.4 (0.3) 1.5 (0.3) 0.1 mean (SEM) 2.5 (0.2) 20.8 (2.1) 18.3 (1.9)
mean (SEM) 1.7 (0.3) 2.9 (0.6) 1.2 (0.3)
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Discussion
Understanding the role of autophagy in cancer has proven to be
challenging in part because of the difficulties in measuring it.
2,8-11 In particular, new methods are needed to measure auto-
phagy in formalin-fixed tumor samples because the evaluation
of this dynamic process using static measurements can be mis-
leading. According to recent guidelines, in order to confirm the
level of autophagy, multiple markers of the autophagic process
should be measured using different assays, but particularly with
an assay of autophagic flux, which represents the overall auto-
phagic degradation activity.9,12 However, the measurement of
autophagic flux, which requires inhibition of the process and
detection of the accumulation of LC3, cannot be performed in
fixed tumors.2,8,9 In searching for a useful model, some investi-
gators have turned to 3D models, which may exhibit the same
autophagic status as that found in tumor,13-15 perhaps because
the 3D environment may acquire the nutrient and metabolic
stress faced by the actual tumor. Here, we used 3D models of
mesothelioma, especially ex vivo tumor cultures, to measure
autophagic flux and then leveraged that information to find a
static marker of autophagy that correlated with the autophagic
flux. With this novel marker, we were able to assess the level of
autophagy in patient tumors and to show for the first time that
higher autophagy in mesothelioma correlates with better clini-
cal outcome.
There has been an active effort to find a useful marker of
autophagy in fixed tumor across many tumor types. In a
search of the literature, we note more than 20 recent studies
in which markers were sought in formalin-fixed tumor tis-
sue and were used to correlate with patient outcome,
including in breast cancer, colon cancer, melanoma, and
ovarian cancer.13,20-30,37-47 These markers (e.g. LC3, BECN1,
and ULK1) were mostly studied by immunohistochemistry
in formalin-fixed tumor without the ability to validate them
by inhibiting the autophagic process to measure autophagic
Figure 5. In tumor fragment spheroids, ATG13 puncta analysis reflects the low or high levels of autophagy. The TFS shown in Figure 4 and not exposed to ammonium
chloride (NH4
C) were fixed, embedded in paraffin, stained for ATG13 (green), KRT/cytokeratin to identify mesothelioma cells (red) and nuclei (blue), and imaged by confo-
cal microscopy. (A) Bars represent the mean percentage of ATG13-positive MPM cells for the TFS determined in Figure 4 to be low or high ATG. Error bars, SEM (B) Repre-
sentative images of TFS with either low autophagy (TFS #8) or high autophagy (TFS #2) levels are shown, with the percentage of mesothelioma cells with ATG13 puncta
(ATG13-positive MPM cells) indicated in parentheses. Zoom-in view of the region in the dashed box shows representative cells with ATG13 puncta (arrowhead). Scale
bars: 10 mm.
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flux. In some cases, the high expression of a marker corre-
lated with poor prognosis; in others, high expression corre-
lated with good prognosis. Without the ability to measure
the autophagic flux in living tumor tissue, these studies
have generally interpreted high expression of a protein as
indicating a high autophagic flux, although, as has been
noted,44 high expression could also mean an impaired
autophagy, with accumulation of the upstream marker.
In this study, our novel contribution is the use of 3D models
to measure autophagic flux in order to find a static marker that
would represent that flux and could then be used for measure-
ment of autophagy in formalin-fixed tissue. We first turned to
the mesothelioma cell lines, in 2D and 3D, and measured auto-
phagic flux. Interestingly, the flux for each cell line was different
in 2D and in 3D, leaving us to wonder which was the more clin-
ically relevant and useful model. When we tested for a static
Figure 6. In tumor fragment spheroids, autophagy initiation correlates with the autophagic flux. (A) TFS exposed to NH4
C were stained for LC3 and the same TFS not
exposed to NH4
C were stained for ATG13; both were stained for KRT/cytokeratin to identify the mesothelioma cells. The correlation plot of the percentages of LC3-posi-
tive MPM cells (y axis, TFS grown in the presence of NH4
C) relative to that of ATG13-positive MPM cells (x axis, TFS grown without NH4C) is shown. Arrows identify the
position of the representative low autophagy TFS (#8, black circle) and high autophagy TFS (#2, gray circle), previously shown on Figures 4 and 5. Spearman rank correla-
tion (rs), 0.8997; P (2-tailed)< 0.0001. (B) TFS grown in the presence or absence of NH4
C for 12 h were stained for ATG13 (green), LC3A/B (red), and nuclei (blue) and
imaged by confocal microscopy. ATG13 and LC3A/B double immunostaining images of a representative TFS with high autophagy levels (TFS #2) grown in the presence
(NH4
C) or absence of the lysosomal inhibitor (CTRL) are shown. Zoom-in views of the regions in the dashed boxes are shown for representative cells. Scale bars: 10 mm.
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marker in 2D or 3D cell cultures, neither the protein levels of
BECN1 nor of ATG13 (Fig. S2) nor the levels of LC3B-II at
baseline (Figs. 1 and 2) correlated with the autophagic flux.
However, ATG13 puncta, which are a marker of ongoing
autophagy initiation,32,34,48 appeared to correlate with the mea-
sured autophagic flux, but only in our 3D multicellular sphe-
roids, not in 2D. Because of this and our previous work,35 we
decided to expand our study of autophagy in 3D models by
including ex vivo tumor. In the ex vivo tumor, we could actu-
ally measure autophagic flux and show that the flux correlated
well with the percentage of mesothelioma cells with ATG13
puncta in the matching formalin-fixed tumor. Then, we tested
this new static marker in a tissue microarray of formalin-fixed
tumor of 109 patients and showed a strong and independent
correlation of ATG13 puncta with clinical outcome, which
encourages us that this experimental approach is worthwhile.
This is the first time in any tumor, to our knowledge, that a
marker was validated across several models, from the 3D in
vitro to 3D ex vivo to paraffin-embedded formalin-fixed tumor.
By the use of these complementary models, we found that
ATG13 puncta reflect the autophagic flux and, most impor-
tantly, correlate with the outcome of patients with mesotheli-
oma, especially with time to recurrence, a highly relevant
clinical endpoint.49 We cannot say whether this marker would
be useful for other tumors; however, we propose that ATG13
could be tested along with other proteins involved in the early
phases of autophagy. The use of ex vivo tumor, if available,
could help in discovery and validation of putative markers.
Figure 7. In tumor fragment spheroids, autophagy initiation correlates with that of the original tumors. Fixed samples of the original tumors used to generate the ana-
lyzed 25 TFS were stained for ATG13 (green), KRT/cytokeratin (red) and nuclei (blue) and imaged by confocal microscopy. (A) The correlation plot of the percentages of
ATG13-positive MPM cells measured in formalin-fixed MPM clinical samples (y axis) relative to those measured in the respective TFS (x axis) is shown. Arrows identify the
position of the representative low autophagy (MPM or TFS #8, black circle) and high autophagy (MPM or TFS #2, gray circle) tumor, previously shown in Figures 4,5, and
6. Spearman rank correlation (rs), 0.9253; P (2-tailed)< 0.0001. (B) Representative images of MPM sections corresponding to TFS with either low autophagy (MPM #8) or
high autophagy (MPM #2) levels are shown, with the percentage of mesothelioma cells with ATG13 puncta (ATG13-positive MPM cells) indicated in parentheses. Zoom-in
view of the region in the dashed box shows representative cells with ATG13 puncta (arrowhead). Scale bars: 10 mm.
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In addition to an intertumoral heterogeneity, autophagy was
also found to show intratumoral heterogeneity. Indeed, in other
immunochemical studies of autophagy markers in tumor, het-
erogeneity of staining has been described.20-22,25,26,28,37,40-46
Here we can confirm, at baseline and then after the use of lyso-
somal inhibitors, that heterogeneity of autophagy within the
mesothelioma tumor is a consistent finding. In every tumor
examined, the autophagy markers (LC3 or ATG13 puncta)
were present in a minority of mesothelioma cells, while the
majority appeared to show little to no expression. We interpret
this to mean that, in the ATG13-positive cells, autophagy is
activated and not impaired, because LC3 accumulates as
expected after lysosomal inhibition. In the ATG13-negative
cells, autophagy is not activated and further investigation is
required to learn whether autophagy can be stimulated in these
cells, as it was in the cell lines by EBSS. The cells do not seem
Figure 8. In formalin-fixed tissue microarray with tumor from 109 patients, ATG13 correlates with clinical outcome. (A) Cox regression analyses, univariate or with correc-
tion for the tumor histology, for death (OS) or recurrence (TTR) are shown. Hazard ratios (HR) with 95% confidence intervals are shown at 18 candidate ATG13% cutpoints.
M, median percentage of ATG13-positive MPM cells. C, selected cutpoint (6%). (B) Kaplan-Meier curves are shown for overall survival (OS) and time to recurrence (TTR) at
the 6% ATG13-positive MPM cells cutpoint selected in (A). (C) Correlation analysis of autophagy levels and known prognostic factors. ATG13 did not correlate with age,
nodal status, gender or tumor volume, anemia, resectability, surgical procedure, adjuvant therapy, or TNM stage; high ATG13 positivity was more common in epithelioid
tumors. (D) Multivariate analysis adjusted for the effect of epithelioid histology shows that ATG13 positivity remains significantly prognostic for TTR (P D 0.0017) and for
OS (P D 0.0166), even after adjusting for the effect of histology. When conservatively corrected for the repeated measures required to establish the cutpoint, ATG13 posi-
tivity remains significantly prognostic for TTR (Bonferroni corrected P D 0.0306) but not for OS (corrected P D 0.2988).
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to differ in phenotype although they may differ in other ways
such as the degree of proliferation or metabolic stress or the
level of intracellular signaling. These cells could possibly repre-
sent stem-like or tumor-initiating cells, which are generally
thought to have elevated levels of autophagy,50 and which are
being studied in mesothelioma.51,52 Genetic or epigenetic het-
erogeneity could be responsible and thus could account for the
finding that the derived TFS maintain the same percentage of
ATG13 positivity as in the original tumor. Although the rea-
sons are still to be uncovered, the intriguing aspect is that the
percentage of ATG13-positive mesothelioma cells gives us
novel information about this tumor by identifying 2 groups of
patients with mesothelioma with a significantly different clini-
cal outcome.
For mesothelioma, this is the first study to show that
autophagy correlates with outcome and to identify a marker,
ATG13, which provides prognostic information independent
of the major known prognostic factors such as age, node status,
gender, tumor volume and histology. The prognostic informa-
tion may derive from the autophagy itself or from an underly-
ing difference in the tumor that is driving the autophagy.
Although these findings will need to be confirmed in additional
cohorts of patients, we suggest that ATG13 holds promise as a
new and independent marker for mesothelioma. And, because
one cannot directly measure the autophagic flux in the fixed
tumor, we propose that confirmation of ATG13 puncta as a
static marker of autophagic flux will require correlation with
other static markers in fixed tumor and comparing those to the
autophagic flux in the matching ex vivo tumor.
Interestingly, our findings indicate that a higher autophagy
initiation status correlates with better clinical outcome. Based
on the current views of autophagy as having a dual role,1,53-57
both as a prosurvival and a tumor-suppressive process, we can
speculate on possible reasons for this correlation. On the one
hand, autophagy may be acting in a tumor-suppressive role, by
playing a cytotoxic role during cancer therapy,56,58,59 or by acti-
vating the immune system.28 On the other hand, autophagy
could be acting in a survival role, as suggested in studies of in
vitro mesothelioma by our group.35,60 In this survival role,
autophagy could be activated by and reflect underlying stresses
in the tumor. Such stresses, such as nutrient deficiency, hyp-
oxia, or uncontrolled proliferation, could render the tumor
more sensitive to therapy and help explain why this group of
patients has a better outcome. Thus, autophagy could be either
a mechanism or a marker of better outcome and it will take fur-
ther studies employing these models to clarify its role in this
tumor.
In conclusion, we have used 3D models of mesothelioma to
identify a marker of autophagy that in turn has prognostic
value in a group of patients with mesothelioma. Our hope is to
use these models to explore the role of autophagy in this tumor.
Materials and methods
Reagents and antibodies
Unless otherwise specified, analytical grade chemicals were from
Sigma-Aldrich Corp. The following primary antibodies were
employed in immunofluorescence or immunoblotting studies:
rabbit monoclonal anti-ATG13 (Cell Signaling Technology,
13468), mouse monoclonal anti-BECN1/Beclin 1 (BD Bioscien-
ces, 612113), mouse monoclonal anti-KRT/cytokeratin clones
AE1/AE3 (Dako North America, M3515), rabbit monoclonal
anti-LC3B (Cell Signaling Technology, 3868), mouse monoclonal
anti-LC3A/B (MBLMedical & Biological Laboratories, M152–3),
and mouse monoclonal anti-TUBA/a-tubulin (Sigma-Aldrich,
T6074). The following secondary antibodies were employed in
immunoblotting: horseradish peroxidase-conjugated goat anti-
mouse IgG (Bio-Rad, 170–6516), horseradish peroxidase-conju-
gated goat anti-rabbit IgG (Bio-Rad, 170–6515). The following
secondary antibodies or fluorescent dyes were employed in
immunofluorescence: Alexa Fluor 546 goat anti-rabbit IgG (Life
Technologies, A11010), biotinylated sheep anti-mouse IgG (GE
Healthcare, RPN1001V ), NeutrAvidin Oregon Green 488 conju-
gate (Life Technologies, A6374), and TOPRO-3 iodide (Life
Technologies, T3605).
Mesothelioma cell lines
Human mesothelioma cell lines M28, REN, SARC, VAMT,
JMN and MSTO-211H were grown from pleural liquid or
tumor and originally obtained from colleagues or ATCC.35
They were all confirmed as mesothelial in origin by staining for
mesothelioma markers (CALB2/calretinin, WT1) and nega-
tively for other markers not seen in mesothelioma (TTF1). All
cells were confirmed to be negative for mycoplasma every 2 mo
by PCR analysis as previously described.61
Monolayer cultures and lysosomal inhibition
Human mesothelioma cell lines were cultured under standard
conditions (37C, 5% CO2) in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal bovine serum and 1%
penicillin-streptomycin solution. For study in parallel with
MCS (see below), 3.2£105 cells were plated on 60-mm Petri
dishes for 24 h. Then, for the next 24 h, the cells received fresh
medium and, for the last 4 h or 8 h, where indicated, exposed
to 10 mM NH4
C or 20 mM HCQ. NH4C and HCQ are lysoso-
motropic compounds that act as weak bases increasing the
lysosomal pH and, in turn, indirectly inhibiting the lysosomal
proteases and the degradation of LC3-II in the autolysosomes.
Note: Prolonged exposure to lysosomal alkalyzers, including
NH4
C, may result in the simultaneous inhibition of the last
phase of autophagy and upregulation of autophagy.9 Thus, to
measure the levels of autophagy, MCS and TFS have been
exposed to NH4
C for no longer than 8 h and 12 h, respectively;
a minimum of 12 h incubation has been suggested for ex vivo
studies of autophagy.9
Spheroid generation and lysosomal inhibition
Multicellular spheroids. MCS were generated in non-adsorbent
round-bottomed 96-well plates, as previously described.62
Briefly, 96-well plates were coated with a 5 mg/ml solution of
polyHEMA (Sigma-Aldrich, P3932) in 95% ethanol and dried
at 37C for 48 h. Plates were sterilized with ultraviolet light for
30 min before use. 104 cells were added to each well and plates
are centrifuged at 800 g for 5 min to bring the cells into contact
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at the bottom of each well. The plates were then placed in a
37C humidified incubator with 5% CO2 for 24 h to allow sphe-
roids to form. For the next 24 h, MCS (nD 32) were transferred
to each well of a polyHEMA-coated 12-well plate, given fresh
media and, for the last 4 or 8 h, where indicated, exposed to
10 mM NH4
C or 20 mMHCQ.
Tumor fragment spheroids. TFS were generated as previously
described,16 from fresh tumor specimens resected from chemo-
naive MPM patients (n D 25) by extrapleural pneumonectomy
or pleurectomy procedures performed at Brigham and Wom-
en’s Hospital in Boston, MA, USA. First, pieces of approxi-
mately 0.5 mm3 were cut from 3 to 5 tumor sections of each
patient, fixed in 10% formalin, embedded in paraffin and proc-
essed for immunofluorescence staining as described below.
Then, for ex vivo spheroid cultures, tumor tissue was diced
finely with scalpels to pieces smaller than 1 mm in diameter.
These TFS were cultured in 100 mm Petri dishes coated with
0.8% Noble agar (Sigma-Aldrich, A5431) in Dulbecco’s modi-
fied Eagle’s medium supplemented with 5% fetal bovine serum
and 1% penicillin-streptomycin solution for 2 or 3 wk. Then,
for the study of autophagy, the TFS were studied for 24 h. At
the start of the 24 h period, TFS (20 to 30) were transferred to
each well of a polyHEMA-coated 24-well plate, exposed to fresh
medium and, for the last 12 h, where indicated, exposed to
10 mM NH4
C.
Immunoblotting
Monolayers or MCS were washed twice with cold phosphate-
buffered saline (DPBS; HyClone, SH30028). Cells were har-
vested in RIPA buffer (1% Nonidet P-40 [Sigma-Aldrich,
74385], 0.5% sodium deoxycholate [Sigma-Aldrich, 30970], 1%
SDS [Sigma-Aldrich, L3771]) supplemented with protease and
phosphatase inhibitor cocktail (Thermo Scientific, 78442) and
homogenized using an ultrasonic cell disruptor (Fisher Scien-
tific). Protein concentration was assessed with DC Protein
Assay (Bio-Rad, 500–0111) and equal amounts of protein
(30 mg of total cell homogenates) were separated by SDS-
PAGE and transferred onto a PVDF membrane (Bio-Rad, 162–
0177). After blocking with 5% nonfat milk (Santa Cruz Biotech-
nology, sc-2324), the filter was probed with designated primary
and secondary antibodies and developed with enhanced chemi-
luminescence substrate (Thermo Scientific, 34080). Bands were
imaged and subjected to densitometry using the BioSpectrum
imaging system apparatus (UVP LLC, Upland, CA, USA)
equipped with the Vision-WorksLS software (UVP LLC). Rep-
resentative images and data of at least 3 independent experi-
ments are shown.
Immunofluorescence
For all immunofluorescence studies, primary or secondary anti-
bodies and fluorescent dyes were diluted in antibody diluent
solution (EMD Millipore, 21544). In each experiment, for LC3
and ATG13 staining, a negative control with the relevant sec-
ondary antibody alone was included. Washes (3x) were per-
formed with TBS (Amresco, 0788)-0.1% Tween 20 (Fisher
Scientific, BP337) after each antibody incubation. For blocking,
slides were incubated with 1% BSA (HyClone, SH30574) in
TBS-0.1% Tween 20 for 30 min. For antigen retrieval, slides
were incubated in citrate buffer (Sigma-Aldrich, C999) and
heated in a pressure cooker for 10 min. For nuclear staining, in
the final staining step, all cells were incubated with TO-PRO-3
iodide (1:1000; Life Technologies, 910576) together with the
secondary antibodies for 2 h. Coverslips or slides were mounted
with ProLong Gold antifade (Life Technologies, P36930).
Images were captured at 63x magnification with a Nikon C1
confocal microscope (Nikon instruments Inc., Melville, NY,
USA).
Monolayers. For ATG13 immunostaining, 4.5£104 cells
were plated on coverslips placed in a 12-well plate and cultured
for a total of 48 h before harvesting. Cells were washed in PBS,
fixed with 4% paraformaldehyde at 4C, blocked and incubated
overnight with rabbit anti-ATG13 antibody at 4 C (1:50). Cells
were then incubated 2 h with Alexa Fluor 546 goat anti-rabbit
IgG antibody (1:200). For LC3 immunostaining, in the shorter
lysosomal inhibition experiments, cells were plated on cover-
slips as above for ATG13 and exposed to the indicated inhibi-
tors for the last 4 h before harvesting; in the longer lysosomal
inhibition experiments, cells were plated on 60 mm Petri dishes
(as described in Monolayer cultures and lysosomal inhibition
section), exposed to the indicated inhibitors for the last 8 h,
and then trypsinized and cytospun onto glass slides
(2£104 cells/slide). Cells on coverslips or on slides were then
washed in PBS, fixed with cold methanol, blocked and incu-
bated overnight with rabbit anti-LC3 antibody at 4C (1:50).
Cells were then incubated 2 h with Alexa Fluor 546 goat anti-
rabbit IgG antibody (1:200).
Multicellular spheroids. MCS were transferred to poly-
HEMA-coated 12-well plates. The cells were trypsinized and
2£104 cells were cytospun onto glass slides. Cells were then
washed in PBS, blocked and processed for ATG13 or LC3
immunostaining as for 2D cultures.
TFS and MPM tumor histology. TFS were collected, fixed
in 10% formalin and embedded in 3% agarose. The agar
pellets were embedded in paraffin. TFS and original MPM
sections (5 mm) were deparaffinized with xylene and rehy-
drated using an ethanol gradient. In tumors, in which mul-
tiple different cell types are present, KRT/cytokeratin
staining is used to identify the mesothelioma cells, as we
have shown.35 For ATG13 and KRT/cytokeratin dual immu-
nostaining, following antigen retrieval, sections were
blocked and incubated overnight with rabbit anti-ATG13
antibody at 4C (1:50); for staining mesothelioma cells, sec-
tions were incubated with mouse anti-KRT/cytokeratin
AE1/AE3 antibody (1:200) for 1 h and, after washes, with
biotinylated sheep anti-mouse IgG (1:200) for 1 h. Sections
were then incubated 2 h with Alexa Fluor 546 goat anti-
rabbit IgG (1:200) and NeutrAvidin Oregon Green 488 con-
jugate (1:200). For LC3 and KRT/cytokeratin dual immu-
nostaining, following antigen retrieval, sections were
incubated 10 min in cold methanol for cell permeabiliza-
tion, washed 2x in PBS, blocked and incubated overnight
with rabbit anti-LC3B antibody at 4C (1:50); for staining
mesothelioma cells, sections were incubated 1 h with mouse
anti-KRT/cytokeratin clones AE1/AE3 antibody (1:200)
for 1 h and, after washes, with biotinylated sheep anti-
mouse IgG (1:200) for 1 h. Sections were then incubated
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with Alexa Fluor 546 goat anti-rabbit IgG (1:200) and
NeutrAvidin Oregon Green 488 conjugate (1:200) for 2 h.
For ATG13 and LC3 dual immunostaining, following anti-
gen retrieval, sections were blocked and incubated overnight
with rabbit anti-ATG13 antibody at 4C (1:50); for staining
LC3, sections were incubated with mouse anti-LC3A/B anti-
body (1:50) for 3 h and, after washes, with biotinylated
sheep anti-mouse IgG (1:200) for 2 h. Sections were then
incubated with Alexa Fluor 546 goat anti-rabbit IgG (1:200)
and NeutrAvidin Oregon Green 488 conjugate (1:200)
for 2 h.
Immunofluorescence puncta analysis
A punctum was defined as a LC3- or ATG13-positive mainly
circular cytoplasmic structure of approximately 1 mm in diame-
ter; this is thought to correspond to an autophagic vesicle (auto-
phagosome or autolysosome) or an early autophagy structure
(omegasome or phagophore). In mesothelioma cell lines, LC3
puncta were counted in a total of 100 cells for each condition
(25 cells in 4 different fields from different experiments); in con-
trast, ATG13 puncta were not counted because they were not
clearly discrete in all conditions. In tumor sections (TFS, original
tumor sections, and tissue microarrays), neither LC3 nor ATG13
puncta were counted because they were not clearly discrete and
thus could not be counted individually. Instead, the percentage
of all mesothelioma cells (KRT/cytokeratin-positive cells) that
showed any LC3 or ATG13 puncta was counted as a measure of
autophagy. On average, 150 KRT/cytokeratin-positive cells were
analyzed for the presence of LC3 or ATG13 puncta from 3 dif-
ferent spheroids (TFS), tumor sections (original tumor), or
tumor cores (tissue microarrays). Images were captured using a
Nikon C1 confocal microscope (Nikon Instruments Inc.,
Melville, NY, USA) at x63 magnification. Saved images were
later counted in a blinded fashion by 2 investigators.
Patients with mesothelioma
Patients whose tumor samples were used in these studies were
participants in a consented and Institutional Review Board-
approved biorepository and clinical database (Dana Farber/Har-
vard Cancer Center protocol #98–063). They underwent surgical
resection of MPM at Brigham andWomen’s Hospital in Boston,
MA without preoperative chemotherapy. Tissue cores of tumor
from 109 patients were obtained from archival clinical paraffin
blocks and incorporated into tissue microarrays, sections of
which were immunostained. Samples of fresh tumor tissue rep-
resenting 25 patients were obtained from discarded portions of
the resection specimen, deidentified and transferred in 4C
media by overnight courier for the preparation of ex vivo tumor
fragment spheroids and formalin-fixed paraffin embedded
blocks for immunostaining. A comprehensive database of
patient demographic, staging, treatment and outcome data was
queried to annotate the tissue microarray. Patient age, gender,
lymph node status, tumor histology, computed tomography-
derived tumor volume (where available), preoperative anemia
(World Health Organization criteria: hemoglobin <12 g/dL for
women, <13 g/dL for men), resectability, surgical procedure
(extrapleural pneumonectomy versus pleurectomy and
decortication), postoperative chemotherapy and/or radiation
therapy prior to recurrence, pathological TNM stage, recurrence
and vital status, recurrence-free interval and overall survival
duration were obtained.
Tissue microarrays
Tissue microarrays were created by the pathology core facilities
of the Dana Farber/Harvard Cancer Center, with coded links to
patient identity under protocol 98–063 (extrapleural pneumo-
nectomy, n D 65; pleurectomy and decortication, n D 36; palli-
ative tumor debulking, n D 6; open biopsy, n D 2). In addition
to anonymous control cores, microarray blocks contained, per
included patient, 3 cores of tumor and, if available, 3 cores of
normal tissue obtained from selected areas of archival clinical
blocks. Five-micron sections were adhered to charged slides
and dipped in paraffin for preservation until ATG13 staining.
Statistical analysis
Data are expressed as mean § standard deviation (SD) or stan-
dard error of the mean (SEM), as appropriate. Differences
between cells in 2D and 3D and between groups with low
autophagy and high autophagy were analyzed by Student t test.
A P value < 0.05 was considered significant. In correlation
plots, correlation analysis was performed to evaluate the Spear-
man rank correlation (rs). A P (2-tailed) value < 0.0001 was
considered significant. GraphPad Prism was employed for sta-
tistical analysis (GraphPad Software Inc., La Jolla, CA, USA). A
putative optimal cutpoint to establish a binary categorical
covariate representing ATG13 positivity was determined based
on minimizing the hazard ratio for recurrence and death within
the middle 2 quartiles using Cox regression. The Fisher exact
test was used to evaluate the association of categorical levels of
ATG13 positivity with established prognostic factors. Kaplan
Meier estimation and log rank comparison of survival func-
tions, and Cox proportional hazards regression, with
Bonferroni correction for multiple testing required to establish
the cutpoint, were used to evaluate the association of ATG13
positivity level with time to tumor recurrence and all-causes of
death following surgery, independently and with adjustment
for tumor histology. StatView version 4.5 software (Abacus
Concepts) was used for outcome analyses.
Abbreviations
BECN1 Beclin 1, autophagy related
2D 2-dimensional
3D 3-dimensional
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3
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MPM malignant pleural mesothelioma
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OS overall survival
TFS tumor fragment spheroids
TTR time to recurrence
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